drugset
Drugs / Opebacan
last change Jun 2010 re-read 3 minutes ago

Opebacan

also known as Bactericidal permeability-increasing protein opebacan · Neuprex · rBPI21
Developed for
graft versus host disease
Investigated by
XOMA (US) LLC

Trials 1

today NCT00454155 · Ph 1/2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT00454155 Feb 2007 → Jun 2010 graft versus host disease XOMA (US) LLC Terminated No outcome recorded Stop: Enrollment

Press releases naming this drug 1 release

DateIssuerRelease
2007-01-09 XOMA (US) LLC XOMA Initiates Clinical Trial of NEUPREX At Harvard Medical School in Allogeneic Hematopoietic Stem Cell Transplantation xoma.com ↗

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Opebacan ClinicalTrials.gov intervention name — accepted as the source's own label NCT00454155 ↗
Known as Bactericidal permeability-increasing protein opebacan ChEMBL registry synonym — accepted as the source's own label CHEMBL2107913 ↗
Known as Neuprex ChEMBL registry synonym — accepted as the source's own label CHEMBL2107913 ↗
Known as rBPI21 “A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)” NCT00454155 ↗
Route Intravenous “IV administration of opebacan” NCT00454155 ↗